National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health Clinical Center (CC)
Observational Model: Cohort
Time Perspective: Prospective
The primary endpoint in this study is overall survival
Survival of HCT subjects vs. conventional therapy subjects, immune reconstitution, engraftment, andclinical outcomes such as infection, autoimmune disease and inflammatory complications, GvHD, growth, and quality of life.
2 Years and older (Child, Adult, Senior)
April 15, 2014
July 1, 2018
July 1, 2019
April 17, 2014
December 28, 2017
National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
† Study has passed its completion date and status has not been verified in more than two years.